Milestone

2019

• Obtained USFDA approval of Vancomycin Hydrochloride Capsules USP and Glyburide Tablets USP

2018

• Methydur® of Orient PHARMA has been granted approval by TFDA

• Construction of the production facilities for subsidiary OP NanoPharma Co., Ltd was completed, marking the beginning of use of Nano-particle Micellar Delivery Technology to produce anti-cancer injectable solutions and powders

2017

• Vietnam office was restructured into a subsidiary of OEP

• A subsidiary was established in Indonesia, expanding the Southeast Asian market

• OEP obtained letter of approval from Taiwan Food and Drug Administration for human organ bank

2016

• The first anti-hyperlipidemia drug developed by OEP was officially launched in Taiwan

• OEP signed a cooperative agreement with American company TissueTech, acquiring exclusive rights for the next series of ophthalmologic tissue products in Asia Pacific and stepping into the field of regenerative medicine

• OEP entered a cooperative agreement with Second Sight, acquiring exclusive distribution rights for the Argus II Retinal Prosthesis System in Taiwan and entering the field of ophthalmology

2014

• Ranked 538th among the top thousand large enterprises named by the CommonWealth Magazine

• Orient PHARMA Co., Ltd had its first ANDA approved by US FDA, officially entered US market

2013

• Ranked 549th among the top thousand large enterprises named by the CommonWealth Magazine

• Signed agreement with Japan’s NanoCarrier Co., Ltd. to develop new cancer drug and construct a new plant

• Orient PHARMA Co., Ltd awarded US Food and Drug Administration Manufacturing Plant Inspection certification

2012

• OEP established a professional dermo-cosmetics sales team in the Philippines, setting up its dermo-cosmetics business in overseas market for the first time

• Orient PHARMA Co., Ltd awarded Japan’s official foreign pharmaceutical manufacturer certification

• Orient PHARMA Co., Ltd officially listed for OTC trading (Stock Code: 4166)

2011

• Orient PHARMA Co., Ltd awarded Taiwan’s Food and Drug Administration PIC/S GMP certification

2010

• Established office in Vietnam, enhancing Southeast Asian channels

2008

• “Karihome” series marketed in China, which Established subsidiary company, Orient PHARMA Co., Ltdwas the first product of OEP entering China market

• Established subsidiary company, Orient PHARMA Co., Ltd

2004

• “Karihome” series marketed in Hong Kong, which was the milk powder business entering overseas market for the first time

2003

• Imported Swedish injectable hyaluronic acid products, becoming the first company in Taiwan to obtain government permit for brands with hyaluronic acid

• Officially listed for OTC trading (Stock Code: 4120)

2002

• Established new offices in Philippines, further expanding the Company’s Southeast Asian territory

• Established the Dermo-cosmetics Division and entered the skincare market

1999

• OEP began deploying its overseas channels in Singapore, Malaysia, and Hong Kong, entering the Southeast Asian markets with prescription medicines

1989

• Imported infant goat formula from New Zealand, and created the first private brand “Karihome” for domestic sales in Taiwan

1982

• Founded Orient EuroPharma Co., Ltd and marketed prescription medicines